OTCMKTS:MKGAF Merck KGaA (MKGAF) Stock Price, News & Analysis $167.57 +0.12 (+0.07%) As of 11/4/2026 03:35 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsOwnershipShort Interest About Merck KGaA Stock (OTCMKTS:MKGAF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Merck KGaA alerts:Sign Up Key Stats Today's Range$166.10▼$170.0150-Day Range$149.97▼$169.4352-Week Range$116.68▼$175.56Volume298 shsAverage Volume619 shsMarket Capitalization$21.66 billionP/E Ratio25.58Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Merck KGaA is a German science and technology company headquartered in Darmstadt, Germany. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The company operates under the name EMD Serono in the United States and Canada, where the Merck name is associated with a separate company. Merck KGaA operates through three primary business sectors: Healthcare, Life Science and Electronics. Its Healthcare business develops and markets prescription medicines, including treatments in oncology, neurology and immunology, as well as fertility and other specialty-care products. The Life Science business supplies laboratory products, equipment, services and technologies used in pharmaceutical manufacturing, biotechnology, research and academic laboratories. The Electronics business develops materials and solutions for the semiconductor and display industries, including specialty chemicals, semiconductor materials and liquid-crystal technologies. Merck KGaA serves customers in markets around the world through research, manufacturing and commercial operations across multiple regions. Belén Garijo has served as the company’s chief executive officer and chair of its executive board since 2021.AI Generated. May Contain Errors. Read More Merck KGaA Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreMKGAF MarketRank™: 1.41878274889 of 5 starsMerck KGaA scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Merck KGaA. Earnings and Valuation3.1 / 5Proj. Earnings Growth8.21% Earnings GrowthEarnings for Merck KGaA are expected to grow by 8.21% in the coming year, from $9.75 to $10.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merck KGaA is 25.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Merck KGaA is 25.58, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.28.Price to Book Value per Share RatioMerck KGaA has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Merck KGaA's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.50% of the float of Merck KGaA has been sold short.Short Interest Ratio / Days to CoverMerck KGaA has a short interest ratio ("days to cover") of 381.01, which indicates bearish sentiment.Change versus previous monthShort interest in Merck KGaA has recently decreased by 28.81%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMerck KGaA does not currently pay a dividend.Dividend GrowthMerck KGaA does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Merck KGaA this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Merck KGaA insiders have not sold or bought any company stock.Percentage Held by Institutions0.10% of the stock of Merck KGaA is held by institutions.Read more about Merck KGaA's insider trading history. Receive MKGAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MKGAF Stock News HeadlinesMerck exits US CDMO operations in sale to LonzaNovember 3 at 6:38 AM | msn.comSilence Therapeutics: Downgrade To Hold On Merck KGaA Acquisition And PV siRNAOctober 19, 2026 | seekingalpha.comThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one recent month, those payments added up to $1,127, without the risks of management decisions or rising mining costs.November 5 at 1:00 AM | Investors Alley (Ad)Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 BillionOctober 19, 2026 | wsj.comMedicare drug pricing model to affect only four firms after Trump’s MFN policyOctober 2, 2026 | msn.comEvinova Launches Strategic Partnership with Merck KGaA, Darmstadt, Germany to Define the Future of Clinical DevelopmentJuly 29, 2026 | businesswire.comMerck's Bio-Techne buyout put Life Sciences sector in focus: top quant-rated stocksJune 25, 2026 | msn.comGermany's Merck boosts life sciences business with $11 billion Bio-Techne dealJune 25, 2026 | cnbc.comSee More Headlines MKGAF Stock Analysis - Frequently Asked Questions How have MKGAF shares performed this year? Merck KGaA's stock was trading at $147.60 at the start of the year. Since then, MKGAF shares have increased by 13.5% and is now trading at $167.5660. How do I buy shares of Merck KGaA? Shares of MKGAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/05/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:MKGAF CIKN/A Webwww.merckgroup.com Phone496151720Fax49-61-5172-2000Employees62,461Year Founded1891Profitability EPS (Trailing Twelve Months)$6.81 Trailing P/E Ratio25.58 Forward P/E Ratio15.88 P/E GrowthN/ANet Income$3.06 billion Net Margins12.60% Pretax Margin15.64% Return on Equity10.17% Return on Assets5.74% Debt Debt-to-Equity Ratio0.27 Current Ratio1.31 Quick Ratio0.84 Sales & Book Value Annual Sales$22.72 billion Price / Sales0.95 Cash Flow$50.47 per share Price / Cash Flow3.32 Book Value$212.00 per share Price / Book0.79Miscellaneous Outstanding Shares129,240,000Free FloatN/AMarket Cap$21.66 billion OptionableNot Optionable Beta0.96 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:MKGAF) was last updated on 11/4/2026 by MarketBeat.com Staff. From Our PartnersThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored$250,000/Month- How You Can Learn from President TrumpPresident Trump has reportedly collected up to $250,000 a month from a single fund. Now investors can get a...The Oxford Club | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThis little-known fund tracks gold and pays out weeklyA little-known $15 fund tied to gold could pay you cash every Friday, no mining stock required. In one rece...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.